Trials / Completed
CompletedNCT02421367
Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- U.S. Army Medical Research and Development Command · Federal
- Sex
- All
- Age
- 20 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
This study is being conducted to evaluate the safety and immunogenicity and antibody persistence of the candidate dengue vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution. | Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type) |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2016-12-01
- Completion
- 2018-03-01
- First posted
- 2015-04-20
- Last updated
- 2019-09-25
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02421367. Inclusion in this directory is not an endorsement.